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Abstract
Background: Patients with common variable immunodeficiency (CVID) have an increased risk of developing
lymphoproliferative diseases, including non-Hodgkins lymphoma (Blood 116:1228–1234, 2010; Blood 119:1650–7, 2012).
The incidence and prognosis of Hodgkin lymphoma in this population is not clear, with only a few case reports in
the literature. Conventional cytotoxic chemotherapy, although highly efficacious in treating Hodgkin lymphoma in
immune competent patients, is problematic in patients with CVID due to the increased risk of infectious complications
(Ther Umsch 69:687–91, 2012; Pediatr Hematol Oncol 24:337–42, 2012). Rituximab and brentuximab vedotin are
both targeted agents used to treat lymphomas that express CD20 and CD30, respectively. Compared to cytotoxic
chemotherapy typically used in Hodgkin lymphoma, these agents are better tolerated with minimal side effects. This
makes them an attractive option for treating lymphoma in patients who have significant co-morbidities, including
those with immune deficiencies. Additionally, rituximab has been used safely to treat autoimmune cytopenias in
patients with CVID5. However, the role of these targeted therapies in CVID-associated Hodgkin lymphoma has not
been reported.
Case Presentation: Here we report the case of a 25 year old female diagnosed with CVID-associated classic Hodgkin
lymphoma, who achieved a complete remission following treatment with rituximab followed by brentuximab vedotin.
Conclusions: We demonstrate that rituximab and brentuximab are likely safe and effective in CVID-associated Hodgkin
lymphoma, providing a feasible and potentially optimal treatment option for this patient population.
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Background
Common variable immunodeficiency (CVID) is a rare im-
mune disorder characterized by decreased immunoglobu-
lin production resulting from a variety of gene defects.
Clinically, patients with CVID have a diverse phenotype,
but can commonly present with recurrent infections,
autoimmune disorders, and lymphoproliferative disorders
including malignancies [1]. Treatment of CVID consists
of lifelong immunoglobulin replacement [2].
The overall incidence of malignant disease appears to be
increased in CVID, with a nearly 5-fold increase compared
to the general population. In a long-term study of 416 pa-
tients with CVID, 38 patients were found to have malig-
nancies, with non-Hodgkin lymphoma (NHL) representing
29 % of the total [3]. Other studies have also shown that
NHL is the most frequent CVID-associated malignancy,
with estimates ranging from 3 to 8 % [1, 3, 4]. However,
there are far fewer reports of Hodgkin lymphoma in CVID
compared to that of NHL. In one cohort of 473 patients
with CVID, 32 patients (6.7 %) developed non-Hodgkin
lymphoma, while there were only 4 cases (0.8 %) of Hodg-
kin lymphoma [5]. Data concerning the prognosis of* Correspondence: hzheng@hmc.psu.edu2Penn State Hershey Cancer Institute, Penn State University College of
Medicine, 500 University Drive, P.O. Box 850, Hershey, PA 17033, USA
Full list of author information is available at the end of the article
© 2016 Rael et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rael et al. Biomarker Research  (2016) 4:7 
DOI 10.1186/s40364-016-0061-8
CVID-related Hodgkin lymphoma are scarce. Among the
four patients mentioned in the prior study, three developed
a B-cell lymphoma years after their initial treatment, two
of whom died of their lymphomas. An additional report
demonstrated a poor clinical outcome in two siblings with
CVID-associated Hodgkin lymphoma. Both patients died
of severe sepsis 6–12 months post chemotherapy with
MOPP/ABVD [6].
Rituximab, a monoclonal antibody to CD20, has been
widely used in B cell NHL. Blockade of CD20 leads to
impaired plasma cell differentiation. The rituximab ther-
apy is associated with re-distribution of B cell popula-
tions to predominantly naïve cells (IgD+ CD27−) with
proportional reductions in switched memory B cells
(IgD− CD27+). Transitional B cells (CD38++ IgM++) can
be elevated or normal post rituximab [7]. IgG levels typ-
ically remain low 9 months after rituximab completion
with impaired carbohydrate pneumococcal vaccine re-
sponses [7]. Rituximab has also been applied in the
treatment for lymphocyte-predominant Hodgkin lymph-
oma, which are usually CD20+ [8]. The role of rituximab
in classic Hodgkin lymphoma is less well established.
Twenty to thirty percent of classic Hodgkin lymphoma
expresses CD20 [9, 10]. It is speculated that rituximab
would be effective in treating CD20+ classic Hodgkin
lymphoma for a variety of reasons including the elimin-
ation of CD20-positive reactive B cells supporting Hodg-
kin and Reed Sternberg (HRS) cells, as well as
elimination of presumptive CD20-positive HRS stem
cells [11, 12]. However, clinical data are extremely lim-
ited. Brentuximab vedotin is an immunotoxin targeting
CD30-expressing cells, including those in Hodgkin
lymphoma [13]. It is approved for treatment of relapse/
refractory Hodgkin lymphoma [14]. Ongoing clinical
studies are testing its efficacy as first line treatment of
Hodgkin lymphoma. Compared to conventional chemo-
therapy, both rituximab and brentuximab vedotin are
better tolerated with less toxicity. Additionally, rituximab
has been successfully used in a population of CVID pa-
tients to treat immune cytopenias [15]. Therefore these
targeted agents represent attractive options for patients
with CVID-associated Hodgkin lymphoma. To date,
clinical data of the role of rituximab and/or brentuximab
vedotin in CVID- associated Hodgkin lymphoma have
not been available.
Here we report a case of a 25 year old female with
CVID-associated classic Hodgkin lymphoma, who achieved
complete remission with treatment of rituximab and bren-
tuximab vedotin.
Case presentation
A 25 year old female was diagnosed of CVID in 2006 (at
age of 18) with initial presentation of recurrent episodes
of bacterial sinusitis and outbreaks of genital herpes.
Laboratory work revealed hypogammaglobulinemia with
poor antibody responses to both polysaccharide and pro-
tein antigens. She was found to have IL-2-Inducible T-
cell kinase (ITK) mutation, which is potentially involved
in the pathogenesis of her CVID. She was started on
IVIG and has been receiving it every month.
The patient has additional history of type 1 diabetes di-
agnosed at 18 months of age, for which she has been de-
pending on insulin, as well as immune thrombocytopenia
purpura (ITP) diagnosed at age of 11. She had multiple
episodes of recurrent thrombocytopenia managed with
IVIG and corticosteroids. In 2002, at the age of 14, she
was hospitalized with a presentation of fever and pain, and
found to have lymphadenopathy, lymphopenia, neutro-
penia, and thrombocytopenia. An extensive infectious
workup was negative. She had bone marrow biopsy, which
was unremarkable with the exception of findings consist-
ent with cytopenias. She ultimately underwent a splenec-
tomy and lymph node resection in 2002. Lymph node and
spleen pathology revealed noncaseating granuloma. After
the splenectomy, her fevers and pain resolved. Her blood
counts have remained relatively normal since splenectomy.
In June 2013 when she was 25 year old, she presented
with left flank pain and fever. A CT scan showed diffuse
lymphadenopathy in chest, abdomen, and pelvis with the
largest node measuring 4.7 × 2.9 cm in the mid abdo-
men. A biopsy of left peri-aortic lymph node showed
non-necrotizing granulomatous inflammation. Extensive
infectious disease and rheumatology workup were all
negative. She was started with prednisone 60 mg daily
for 7 days before being tapered down, with clinical im-
provement. In September 2013, she was hospitalized
again with abdominal pain and fever. A PET scan was
done and showed extensive hypermetabolic lymphaden-
opathy involving the supraclavicular, bilateral axillary,
right internal mammary, mediastinal, retroperitoneal,
mesenteric, and pelvic lymph node chains. In addition,
there were hypermetabolic sclerotic lesions within the
bone marrow of L3 and the left iliac bone (Fig. 2a). She
underwent left iliac bone marrow biopsy which revealed
a diagnosis of EBV-positive immunodeficiency (CVID)-
associated lymphoproliferative disorder, classical Hodgkin’s
lymphoma morphology and immunophenotype. The ab-
normal cells were large cells positive for CD30, CD15,
CD20 (weak to moderate), and PAX-5 (weak), EBER posi-
tive (Fig. 1). She had no other constitutional symptoms. La-
boratory work demonstrated normal CBC. LDH was mildly
elevated at 853 unit/L (normal range 313–618 unit/L).
Given her history of CVID, with the immunopheno-
type of her lymphoma, the decision was made to start
therapy with rituximab monotherapy. The patient com-
pleted four weekly doses of rituximab dosed at 375 mg/m2.
She had significant clinical improvement with resolution of
fever and abdominal pain. LDH decreased to normal range
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as well. Follow-up PET/CT in January 2014 showed near-
complete metabolic response in the hilar, mediastinal, axil-
lary, retroperitoneal, mesenteric, iliac, and inguinal lymph
nodes. However, there was only a partial metabolic re-
sponse of the lesions in the left iliac bone, vertebral bodies
T9 and L3 (Fig. 2b). Subsequently, an L3 vertebral body bi-
opsy was pursued, with pathology consistent with the previ-
ous diagnosis of classic Hodgkin lymphoma, although with
an immunophenotype that was now CD20-negative. She
was referred to Radiation Oncology and received a course
of 4000 cGy to the spine. She then received four additional
weekly treatments of rituximab. Repeat PET/CT in June
2014 showed resolution of the L3 lesion, but revealed new
sites of osseous disease in the right humerus, left posterior
5th rib, left 10th spinous process, mid sacrum, right iliac
wing, and left femoral head (Fig. 2c). Brentuximab vedotin
1.8 mg/kg every 3 weeks was initiated in July 2014. The
patient completed ten doses of brentuximab vedotin be-
fore discontinuing due to moderate neuropathy. She also
received maintenance rituximab every 2 months. A
follow-up PET/CT in December 2014 showed a complete
metabolic response (Fig. 2d). Rituximab bimonthly has
been maintained with good tolerance. She is doing well
with no evidence of disease recurrence to date.
Discussion
The risk of lymphoma among patients with CVID is
clearly higher than that of general population. In a
Fig. 1 Histology of the bone marrow biopsy at the diagnosis CVID-associated classic Hodgkin lymphoma. a Photomicrograph of the infiltrate in
the marrow comprising very large Hodgkin and Reed-Sternberg (HRS) cells in a fibroinflammatory background (Hematoxylin and eosin stain, 1000X).
b & c CD30 and CD20 immunohistochemistry is positive in HRS cells respectively (3′,3′-diaminobenzidine chromogen with hematoxylin counterstain,
1000X). d In situ hybridization for Epstein-Barr-virus-encoded RNA 1 (EBER 1) is positive in HRS cells (INFORM EBER probe and iVIEWTMblue detection,
Ventana Medical Systems, Inc., Tuscon, AZ. 1000X)
Fig. 2 PET scan prior to and post treatment. a PET scan on initial diagnosis of CVID-associated classic Hodgkin lymphoma. b Post 4 weekly doses
of rituximab. c Prior to brentuximab vidotin. d Post brentuximab
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combined Danish and Swedish study of 176 patients
with CVID, the incidence of non-Hodgkin lymphoma
was 12.1-fold higher, and the incidence of Hodgkin
lymphoma was 16.7-fold higher compared to that of
regular population [16]. CVID-associated lymphomas
are typically extra-nodal, B-cell derived and EBV nega-
tive [17]. The diagnosis of lymphoma in patients with
CVID can be challenging as localized or systemic granu-
lomatous disease and lymphoid hyperplasia are also fre-
quently observed in this patient population [18]. As
occurred in this case, initial lymph node biopsy when
lymphadenopathy is discovered on body imaging is often
nonspecific and nonmalignant. Repeat tissue sampling,
given the chronicity of CVID, is essential to provide a
timely diagnosis of malignancy in these patients.
The pathogenesis of lymphomas among patients with
CVID is not well understood, but likely attributes to gen-
etic disorder, immune dysregulation, and chronic infec-
tions. It has been postulated that the underlying immune
deficient status increases the susceptibility to virus infec-
tion and the development of viral-related lymphoma (e.g.
EBV associated lymphoma). In contrast to this hypothesis,
most CVID-associated lymphoma is EBV negative [17].
Our patient does have EBV positive CVID-associated
lymphoma. Whether the EBV status contributes to the
pathogenesis of her lymphoma or it is just co-incident re-
mains unknown. Genetic disorders in patient with CVID
are heterogeneous. Our patient does have a mutation of
ITK, which belongs to the Tec family of non-receptor
tyrosine kinases. There are five members in Tec family:
ITK, RLK (Resting lymphocyte kinase), BTK (Bruton’s
tyrosine kinase), TEC (Tyrosine kinase expressed in hepa-
tocellular carcinoma), and BMX (Bone marrow tyrosine
kinase gene on chromosome X). ITK deficiency is a T-cell
immunodeficiency that has been implicated in the devel-
opment of EBV-positive lymphoproliferative disorders, in-
cluding Hodgkins and Hodgkins-like lymphoma [19]. Our
case provides the first clinic association between ITK mu-
tation and CVID. Whether ITK plays a role in the patho-
genesis of CVID-associated Hodgkin lymphoma and thus
a potential target for the therapeutics of this disease is
worth further studying.
Granulomatous disease is a common manifestation of
CVID, occurring in 8–22 % patients [20–22]. As in our
case, it is frequently noted even before the diagnosis of
CVID. It has been observed that granulomatosis in
CVID is associated with poor prognosis and there is no
standard treatment. Most physicians choose to observa-
tion or a course of steroid if symptomatic. Long term
steroid is challenging given multiple side effects includ-
ing high risk of infections. Our patient did have non-
caseating granulomas proved by multiple lymph node
biopsies. Interestingly after initial treatment of rituxi-
mab, in addition to improvement of the metabolic active
bone lesions, there was near-completed response in the
extensive lymphadenopathy. Some of the lymph nodes
were biopsy proven non-caseating granulomas. There-
fore rituximab is potentially a promising therapeutic
CVID related granulomatosis. Further study is warran-
tied to determine the efficacy and long term survival.
The prognosis for patients with CVID-associated
Hodgkin lymphomas is unfortunately not well defined,
likely due to the rareness of this disease. Our extensive
literature search only located a case report in which two
siblings found to have CVID-associated Hodgkin lymph-
oma at age of 11 and 15 respectively. However both died
of severe infection 6–12 months post intensive chemo-
therapy [6]. One challenge is that the standard chemo-
therapy (e.g. ABVD) that are applied to patients with
Hodgkin lymphoma who are immune competent, may
not be tolerated by CVID patients because of the high
risk and severity of infections resulting from immune
deficiency. In our case, we chose rituximab and brentux-
imab instead of conventional chemotherapy as the first
line treatment. The majority of classic Hodgkin lymph-
oma express CD30. In addition, 20 to 30 % of them ex-
press CD20 [9, 10]. Our patient did have expression of
both CD20 and CD30 in her classic Hodgkin lymphoma,
making a strong rationale for the treatment with rituxi-
mab and brentuximab, agents targeting CD20 and CD30
respectively. In fact, we were able to achieve complete
response without major complications.
Conclusion
In summary, we report a case of a 25 year old female
diagnosed with CVID-associated classic Hodgkin lymph-
oma, who achieved a complete remission following treat-
ment with rituximab followed by brentuximab vedotin.
To our knowledge, our case is the first to demonstrate
that rituximab and brentuximab are likely safe and ef-
fective in CVID-associated Hodgkin lymphoma, provid-
ing a feasible and potentially optimal treatment option
for this patient population.
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